vs
ONTO INNOVATION INC.（ONTO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ONTO INNOVATION INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$218.2M vs $207.3M），ONTO INNOVATION INC.净利率更高（12.9% vs -62.0%，领先75.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -13.5%），ONTO INNOVATION INC.自由现金流更多（$82.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.6%）
Onto Innovation是一家美国半导体企业，2019年由Rudolph Technologies与Nanometrics合并组建，为微电子制造行业提供生产工艺、工艺控制相关设备及配套软件解决方案，是全球半导体制造支撑领域的重要供应商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ONTO vs RARE — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $218.2M | $207.3M |
| 净利润 | $28.2M | $-128.6M |
| 毛利率 | 50.7% | — |
| 营业利润率 | 10.9% | -54.7% |
| 净利率 | 12.9% | -62.0% |
| 营收同比 | -13.5% | 25.9% |
| 净利润同比 | -46.8% | 3.5% |
| 每股收益（稀释后） | $0.57 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $207.3M | ||
| Q3 25 | $218.2M | $159.9M | ||
| Q2 25 | $253.6M | $166.5M | ||
| Q1 25 | $266.6M | $139.3M | ||
| Q4 24 | $263.9M | $164.6M | ||
| Q3 24 | $252.2M | $139.5M | ||
| Q2 24 | $242.3M | $147.0M | ||
| Q1 24 | $228.8M | $108.8M |
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $28.2M | $-180.4M | ||
| Q2 25 | $33.9M | $-115.0M | ||
| Q1 25 | $64.1M | $-151.1M | ||
| Q4 24 | $48.8M | $-133.2M | ||
| Q3 24 | $53.1M | $-133.5M | ||
| Q2 24 | $52.9M | $-131.6M | ||
| Q1 24 | $46.9M | $-170.7M |
| Q4 25 | — | — | ||
| Q3 25 | 50.7% | — | ||
| Q2 25 | 48.2% | — | ||
| Q1 25 | 53.7% | — | ||
| Q4 24 | 50.2% | — | ||
| Q3 24 | 54.1% | — | ||
| Q2 24 | 52.9% | — | ||
| Q1 24 | 51.7% | — |
| Q4 25 | — | -54.7% | ||
| Q3 25 | 10.9% | -106.9% | ||
| Q2 25 | 12.7% | -64.8% | ||
| Q1 25 | 23.7% | -102.6% | ||
| Q4 24 | 16.1% | -74.3% | ||
| Q3 24 | 21.0% | -94.6% | ||
| Q2 24 | 20.2% | -79.1% | ||
| Q1 24 | 18.7% | -151.9% |
| Q4 25 | — | -62.0% | ||
| Q3 25 | 12.9% | -112.8% | ||
| Q2 25 | 13.4% | -69.0% | ||
| Q1 25 | 24.0% | -108.5% | ||
| Q4 24 | 18.5% | -80.9% | ||
| Q3 24 | 21.0% | -95.7% | ||
| Q2 24 | 21.9% | -89.5% | ||
| Q1 24 | 20.5% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $0.57 | $-1.81 | ||
| Q2 25 | $0.69 | $-1.17 | ||
| Q1 25 | $1.30 | $-1.57 | ||
| Q4 24 | $0.98 | $-1.34 | ||
| Q3 24 | $1.07 | $-1.40 | ||
| Q2 24 | $1.07 | $-1.52 | ||
| Q1 24 | $0.94 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $603.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $-80.0M |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | $603.1M | $202.5M | ||
| Q2 25 | $217.5M | $176.3M | ||
| Q1 25 | $203.7M | $127.1M | ||
| Q4 24 | $212.9M | $174.0M | ||
| Q3 24 | $188.7M | $150.6M | ||
| Q2 24 | $172.6M | $480.7M | ||
| Q1 24 | $190.9M | $112.3M |
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $2.0B | $9.2M | ||
| Q2 25 | $2.0B | $151.3M | ||
| Q1 25 | $1.9B | $144.2M | ||
| Q4 24 | $1.9B | $255.0M | ||
| Q3 24 | $1.9B | $346.8M | ||
| Q2 24 | $1.8B | $432.4M | ||
| Q1 24 | $1.8B | $140.3M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $2.2B | $1.2B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $2.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $82.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 37.6% | -48.6% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.95× | — |
| 过去12个月自由现金流最近4个季度 | $261.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $83.4M | $-91.4M | ||
| Q2 25 | $57.9M | $-108.3M | ||
| Q1 25 | $92.0M | $-166.5M | ||
| Q4 24 | $56.0M | $-79.3M | ||
| Q3 24 | $67.2M | $-67.0M | ||
| Q2 24 | $65.3M | $-77.0M | ||
| Q1 24 | $57.1M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $82.0M | $-92.7M | ||
| Q2 25 | $44.2M | $-110.7M | ||
| Q1 25 | $83.7M | $-167.8M | ||
| Q4 24 | $51.4M | $-79.5M | ||
| Q3 24 | $59.2M | $-68.6M | ||
| Q2 24 | $53.0M | $-79.0M | ||
| Q1 24 | $50.2M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | 37.6% | -58.0% | ||
| Q2 25 | 17.4% | -66.5% | ||
| Q1 25 | 31.4% | -120.5% | ||
| Q4 24 | 19.5% | -48.3% | ||
| Q3 24 | 23.5% | -49.2% | ||
| Q2 24 | 21.9% | -53.7% | ||
| Q1 24 | 21.9% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.6% | 0.8% | ||
| Q2 25 | 5.4% | 1.5% | ||
| Q1 25 | 3.1% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 5.1% | 1.4% | ||
| Q1 24 | 3.0% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.23× | — | ||
| Q1 24 | 1.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONTO
| Systems And Software Revenue | $173.8M | 80% |
| Parts Revenue | $23.9M | 11% |
| Service Revenue | $20.5M | 9% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
